• Consensus Rating: Buy
  • Consensus Price Target: $23.63
  • Forecasted Upside: 93.01%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$12.24
▼ -0.5 (-3.92%)

This chart shows the closing price for ATEC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alphatec Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATEC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATEC

Analyst Price Target is $23.63
▲ +93.01% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Alphatec in the last 3 months. The average price target is $23.63, with a high forecast of $32.00 and a low forecast of $17.00. The average price target represents a 93.01% upside from the last price of $12.24.

This chart shows the closing price for ATEC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Alphatec. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/2/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/31/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2024Needham & Company LLCBoost TargetBuy ➝ Buy$22.00 ➝ $23.00Low
3/20/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$25.00Low
3/20/2024Needham & Company LLCBoost TargetBuy ➝ Buy$19.00 ➝ $22.00Low
3/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00Low
2/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$19.00Low
2/9/2024Wells Fargo & CompanyInitiated CoverageOverweight$26.00Low
12/19/2023Needham & Company LLCBoost TargetBuy ➝ Buy$16.00 ➝ $18.00Low
11/14/2023Morgan StanleyLower TargetOverweight ➝ Overweight$23.00 ➝ $17.00Low
11/7/2023Stifel NicolausLower TargetBuy ➝ Buy$25.00 ➝ $24.00Low
11/7/2023Needham & Company LLCLower TargetBuy ➝ Buy$20.00 ➝ $16.00Low
10/20/2023Roth MkmInitiated CoverageBuy$22.00Low
8/4/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$19.00 ➝ $23.00Low
8/4/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$17.00 ➝ $22.00Low
8/4/2023Needham & Company LLCBoost TargetBuy ➝ Buy$19.00 ➝ $20.00Low
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00Low
8/4/2023Stifel NicolausBoost TargetBuy ➝ Buy$18.00 ➝ $25.00Low
6/26/2023Lake Street CapitalBoost Target$20.00 ➝ $32.00Low
4/17/2023Needham & Company LLCReiterated RatingBuy$18.00Low
3/1/2023HC WainwrightReiterated RatingBuy$20.00Low
3/1/2023Needham & Company LLCReiterated RatingBuy$18.00Low
3/1/2023Morgan StanleyBoost TargetOverweight$17.00 ➝ $18.00Low
1/12/2023Lake Street CapitalBoost TargetBuy$16.50 ➝ $20.00Low
1/6/2023Morgan StanleyBoost TargetOverweight$15.00 ➝ $17.00Low
11/4/2022Needham & Company LLCBoost TargetBuy$13.00 ➝ $14.00Low
10/17/2022Lake Street CapitalBoost Target$13.00 ➝ $16.50Low
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$12.00Low
10/11/2022Morgan StanleyBoost TargetOverweight$13.00 ➝ $15.00Low
9/12/2022Morgan StanleyInitiated CoverageOverweight$13.00Low
8/8/2022The Goldman Sachs GroupLower TargetNeutral$11.00 ➝ $9.50Low
7/15/2022Lake Street CapitalReiterated RatingBuy$9.00Low
5/26/2022Needham & Company LLCLower TargetBuy$15.00 ➝ $13.00Low
5/6/2022HC WainwrightBoost Target$19.00 ➝ $20.00High
3/2/2022Piper SandlerLower TargetOverweight$22.00 ➝ $17.00High
12/3/2021The Goldman Sachs GroupInitiated CoverageNeutral$12.50High
11/5/2021Needham & Company LLCLower TargetBuy$18.00 ➝ $15.00High
10/28/2021Loop CapitalInitiated CoverageBuy$22.00Low
8/25/2021Needham & Company LLCInitiated CoverageBuy$18.00Medium
8/4/2021CowenInitiated CoverageOutperform$22.50High
8/4/2021Piper SandlerBoost TargetOverweight$19.00 ➝ $22.00High
3/5/2021Piper SandlerBoost TargetOverweight$17.00 ➝ $19.00High
3/5/2021HC WainwrightBoost TargetBuy$16.00 ➝ $19.00High
1/29/2021Piper SandlerBoost TargetOverweight$12.00 ➝ $17.00Low
12/21/2020HC WainwrightReiterated RatingBuy$12.00 ➝ $16.00High
12/18/2020Lake Street CapitalBoost Target$15.00 ➝ $20.00High
10/19/2020Stifel NicolausInitiated CoverageBuy$13.00Medium
10/12/2020HC WainwrightBoost TargetBuy$9.00 ➝ $12.00Low
10/8/2020Lake Street CapitalBoost TargetBuy$13.00 ➝ $15.00High
9/3/2020CowenInitiated CoverageOutperform$12.00High
6/18/2020Northland SecuritiesInitiated CoverageOutperform$9.00Medium
4/9/2020HC WainwrightReiterated RatingBuy$9.50 ➝ $7.50Medium
3/6/2020HC WainwrightReiterated RatingBuy$8.00 ➝ $9.50High
1/14/2020Lake Street CapitalBoost TargetBuy$10.00 ➝ $15.00Medium
1/14/2020HC WainwrightReiterated RatingBuyHigh
10/31/2019Lake Street CapitalBoost TargetBuy$7.00 ➝ $10.00High
10/31/2019Piper Sandler CompaniesBoost TargetOverweight$7.00 ➝ $9.00High
8/6/2019HC WainwrightBoost TargetBuy$4.00 ➝ $6.00Low
8/5/2019Piper Sandler CompaniesInitiated CoverageOverweight ➝ Overweight$7.00High
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.77 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/29/2023
  • 4 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2023
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/28/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/27/2024
  • 9 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/26/2024
  • 23 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/27/2024
  • 8 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/26/2024

Current Sentiment

  • 8 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Alphatec logo
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Read More

Today's Range

Now: $12.24
Low: $12.12
High: $12.62

50 Day Range

MA: $13.76
Low: $12.34
High: $15.64

52 Week Range

Now: $12.24
Low: $8.66
High: $19.14

Volume

1,341,175 shs

Average Volume

1,618,758 shs

Market Capitalization

$1.69 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Alphatec?

The following sell-side analysts have issued reports on Alphatec in the last year: Canaccord Genuity Group Inc., HC Wainwright, Lake Street Capital, Morgan Stanley, Needham & Company LLC, Roth Mkm, Stifel Nicolaus, StockNews.com, and Wells Fargo & Company.
View the latest analyst ratings for ATEC.

What is the current price target for Alphatec?

8 Wall Street analysts have set twelve-month price targets for Alphatec in the last year. Their average twelve-month price target is $23.63, suggesting a possible upside of 93.0%. Lake Street Capital has the highest price target set, predicting ATEC will reach $32.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $17.00 for Alphatec in the next year.
View the latest price targets for ATEC.

What is the current consensus analyst rating for Alphatec?

Alphatec currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATEC will outperform the market and that investors should add to their positions of Alphatec.
View the latest ratings for ATEC.

What other companies compete with Alphatec?

How do I contact Alphatec's investor relations team?

Alphatec's physical mailing address is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. The medical technology company's listed phone number is (760) 431-9286 and its investor relations email address is [email protected]. The official website for Alphatec is www.atecspine.com. Learn More about contacing Alphatec investor relations.